IDEAYA Biosciences (IDYA) – Research Analysts’ Recent Ratings Changes

by · The Cerbat Gem

A number of research firms have changed their ratings and price targets for IDEAYA Biosciences (NASDAQ: IDYA):

  • 4/21/2026 – IDEAYA Biosciences had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 4/18/2026 – IDEAYA Biosciences was upgraded by Wall Street Zen from “sell” to “hold”.
  • 4/14/2026 – IDEAYA Biosciences had its price target raised by Royal Bank Of Canada from $49.00 to $53.00. They now have an “outperform” rating on the stock.
  • 4/14/2026 – IDEAYA Biosciences had its price target raised by The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a “neutral” rating on the stock.
  • 4/14/2026 – IDEAYA Biosciences had its price target raised by Wells Fargo & Company from $44.00 to $48.00. They now have an “overweight” rating on the stock.
  • 4/14/2026 – IDEAYA Biosciences had its price target raised by Wedbush from $52.00 to $58.00. They now have an “outperform” rating on the stock.
  • 4/14/2026 – IDEAYA Biosciences had its price target raised by Guggenheim from $50.00 to $54.00. They now have a “buy” rating on the stock.
  • 4/13/2026 – IDEAYA Biosciences was given a new $65.00 price target by Truist Financial Corporation.
  • 3/31/2026 – IDEAYA Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $52.00 price target on the stock.

Insider Buying and Selling at IDEAYA Biosciences

In other news, Director Jeffrey Stein acquired 50,000 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was acquired at an average price of $32.96 per share, with a total value of $1,648,000.00. Following the completion of the transaction, the director directly owned 54,281 shares in the company, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.50% of the stock is currently owned by corporate insiders.

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

Read More